Pharmacy News

Gilead Recalls Vistide Lot B120217A

Cheryl A. Thompson

BETHESDA, MD 19 Feb 2013—Gilead Sciences Inc. on February 15 announced a recall of Vistide lot B120217A because particulate matter had been found in some of the vials in that lot of cidofovir injection.

The company at the time said it was "not currently aware of any complaint attributable to the particles."

According to the FDA-approved labeling for Vistide, the product is for use in the treatment of cytomegalovirus retinitis in patients with AIDS. The clear, colorless solution is for i.v. infusion, not intraocular injection.

Gilead said lot B120217A was distributed to wholesalers, hospital pharmacies, and community pharmacies.

Information on returning vials in that lot is available from Stericycle at 888-965-5791, 8 a.m. to 8 p.m. Eastern Time Monday through Friday.


Contact Us
For questions, comments, or more information on this article, please contact the ASHP News Center at
ASHP Product Listing